QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.103.052324v1 306/3/934    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuwayhid, S. J. Articles by Werling, L. L. Search for Related Content PubMed PubMed Citation Articles by Nuwayhid, S. J. Articles by Werling, L. L.

NEUROPHARMACOLOGY

Steroids Modulate N-Methyl-D-aspartate-Stimulated [³H]Dopamine Release from Rat Striatum via Receptors

Department of Pharmacology, George Washington University Medical Center, Washington, DC

Received March 31, 2003; accepted May 13, 2003.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Steroids have been proposed as endogenous ligands at receptors. In the current study, we examined the ability of steroids to regulate N-methyl-D-aspartate (NMDA)-stimulated [³H]dopamine release from slices of rat striatal tissue. We found that both progesterone and pregnenolone inhibit [³H]dopamine release in a concentration-dependent manner similarly to prototypical agonists, such as (+)-pentazocine. The inhibition seen by both progesterone and pregnenolone exhibits IC₅₀ values consistent with reported K_i values for these steroids obtained in binding studies, and was fully reversed by both the ₁ antagonist 1-(cyclopropylmethyl)-4-2'-4''flurophenyl)-2'oxoethyl)piperidine HBr (DuP734) and the ₂ antagonist 1'-[4-[1-(4-fluorophenyl)-1-H-indol-3-yl]-1-butyl]spiro[iso-benzofuran-1(3H), 4'piperidine] (Lu28-179). Lastly, to determine whether a protein kinase C (PKC) signaling system might be involved in the inhibition of NMDA-stimulated [³H]dopamine release, we tested the PKC-selective inhibitor 5,21:12,17-dimetheno-18H-dibenzo[i,o]pyrrolo[3,4 - 1][1,8]diacyclohexadecine-18,20(19H)-dione,8-[(dimethylamino)methyl]-6,7,8,9,10,11-hexahydro-monomethanesulfonate (9Cl) (LY379196) against both progesterone and pregnenolone. We found that LY379196 at 30 nM reversed the inhibition of release by both progesterone and pregnenolone. These findings support steroids as candidates for endogenous ligands at receptors.

Steroids were originally proposed as endogenous ligands at receptors by Su et al. (1988). Swartz et al. (1989) questioned this proposal because they assumed steroids could not be produced in the brain, and the concentration of steroids crossing the blood-brain barrier would not suffice to occupy receptors. Interest in steroid- receptor interactions was revived when studies showed that steroids mediated many effects through a nongenomic mechanism (Falkenstein et al., 2000) and that steroids were synthesized in the brain (Hu et al., 1987; Jung-Testas et al., 1989; Guarneri et al., 2000), along with pharmacological studies on regulation of transmitter release (Monnet et al., 1995) and responses in hippocampal neurons (Bergeron et al., 1996) to steroids. The steroids the Su group found that competed best for [³H]SKF10,047 at ₁ sites were progesterone, deoxycortisone, and testosterone. More recently, McCann and Su (1994) examined steroid competition at ₁ sites and found both progesterone and testosterone had an affinity for ₁ and ₂ subtypes.

Monnet et al. (1995) described the modulation of NMDA-stimulated [³H]norepinephrine release by progesterone, dehydroepiandrosterone sulfate (DHEA S), and pregnenolone sulfate (PREG S) in rat hippocampal slices. The effects were blocked by receptor antagonists and progesterone acted as an antagonist to DHEA S and PREG S. Most recently, Meyer et al. (2002) showed that PREG S enhances glutamate release from hippocampal slices via a ₁-like receptor. In studies reviewed by Bastianetto et al. (1999) and Maurice et al. (1999), PREG S, DHEA S, and allotetrahydroxycorticosterone show antistress, anxiolytic, and antiamnesiac activity that is blocked by antagonists, as well as antisense oligonucleotides to ₁ receptors (Maurice et al., 2001). Taking all these studies in consideration, steroids at this time are likely candidates for endogenous receptor ligands.

Gonzalez-Alvear and Werling (1994) first demonstrated regulation of NMDA-stimulated [³H]dopamine release from rat striatum by receptor ligands, including (+)-pentazocine, (+)-SKF10,047, and BD737. The inhibition produced by low concentrations of these ligands was reversed by the ₁ antagonist DuP734 (Gonzalez-Alvear and Werling, 1994, 1995). A second phase of inhibition produced by higher concentrations of (+)-pentazocine was reversed by nonsubtype-selective receptor antagonists, indicating the participation of ₂ receptors. Studies by Izenwasser et al. (1998) revealed that amphetamine-stimulated [³H]dopamine release can be modulated by ₂ receptor agonists and antagonists in vitro. In our current study, we examined the ability of steroids to regulate NMDA-stimulated [³H]dopamine release from rat striatal slices via receptors. If steroids are indeed the endogenous ligand for receptors, they should affect neurotransmitter release and signaling similarly to prototypical ligands. We have previously demonstrated that ₁ agonist-mediated inhibition of NMDA-stimulated [³H]dopamine release is mediated by a PKC signaling system, likely involving the isoform. receptor regulation of release is abolished by pretreatment with phorbol 12-myristate 13-acetate, as well by treatment with a PKC or a PLC inhibitor (Nuwayhid and Werling, 2003). Therefore, we tested whether the same PKC pathway is involved in regulation of stimulated dopamine release by steroids via receptors by using a PKC inhibitor.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Drugs and Reagents. The following chemicals were kindly provided by or obtained from the following sources: domperidone and nomifensine (Sigma/RBI, Natick, MA); L-ascorbic acid, pregnenolone, testosterone, progesterone, dihydoisoandosterone, cholesterol, and mifepristone (Sigma-Aldrich, St. Louis, MO); [³H]dopamine (Amersham Biosciences Inc., Piscataway, NJ); LY379196 (gift of Dr. Robin Bowman, Eli Lilly & Co., Indianapolis, IN); trilostane (gift of Dr. J. Puddefoote; Queen Mary and Westfield College, London, UK); DuP734 (DuPont Merck Pharmaceutical Co., Wilmington, DE); and Lu28-179 (H. Lundbeck, Copenhagen, Denmark).

Measurement of Stimulated [³H]Dopamine Release from Striatal Slices. All experiments were carried out in accordance with the guidelines and the approval of the George Washington University Institutional Animal Use and Care Committee. Male Sprague-Dawley rats (Hilltop Lab Animals, Scottsdale, PA), weighing 200 to 225 g, were sacrificed by decapitation, and brains removed to ice. Striata were dissected, chopped in two planes at right angles into 250 x 250 µm strips with a Sorvall T-2 tissue sectioner, and suspended in modified Krebs-HEPES buffer (MKB; 127 mM NaCl, 5 mM KCl, 1.3 mM NaH₂PO₄, 2.5 mM CaCl₂, 15 mM HEPES, 10 mM glucose, pH adjusted to 7.4 with NaOH) by titration through a plastic pipette. Buffers were oxygenated throughout the experiments and brain slices were kept at a constant temperature of 37°C. After three washes in MKB, tissue was resuspended in 20 ml of MKB and incubated for 30 min with 0.1 mM ascorbic acid and 15 nM [³H]dopamine. Tissue was then washed twice with 20 ml of MKB and once in 20 ml of MKB containing 10 µM nomifensine and 1 µM domperidone. These drugs were included in all subsequent steps to prevent reuptake of and feedback inhibition by the released [³H]dopamine. Tissue was suspended a final time in 7.5 ml of MKB, containing 10 µM nomifensine and 1 µM domperidone, and distributed in 275-µl aliquots between glass fiber discs into chambers of a superfusion apparatus (Brandel, Inc., Gaithersburg, MD). MKB was superfused over tissue at a rate of 0.6 ml/min. A low stable baseline release of approximately 1.3%/2 min collection interval was established over a 30-min period. Tissue was then stimulated by a 2-min exposure to 25 µM NMDA (S1). The mean fractional release (percentage) produced in the S1 stimulus interval was 11.9 ± 1.2%. Inflow was then returned to nonstimulating buffer during a 10-min interstimulus interval (ISI). If a steroid, antagonist, cholesterol, mifepristone, or trilostane was being tested, it was included at this time. The inclusion of antagonist drug in the buffer did not significantly affect basal release (per 2-min collection interval: no antagonist 1.3 ± 0.33, n = 3; 100 nM DuP734, 1.2 ± 0.24, n = 3; 1 nM Lu28-179 1.4 ± 0.14, n = 3). Neither did inclusion of steroid affect basal release significantly (progesterone, 1.3 ± 0.24, n = 4; pregnenolone, 1.6 ± 0.09, n = 3). Tissue was then exposed to a second stimulus (S2) identical to the first except in the presence of a steroid, trilostane, mifepristone, or cholesterol, as appropriate. In the experiments testing the PKC inhibitor LY379196, the drug was present throughout S1, ISI, and S2. Inflow was once again returned to nonstimulating buffer before extraction of the remaining radioactivity in the tissue by a 45-min exposure to 0.2 N HCl at a reduced flow rate. Superfusates were collected at 2-min intervals in scintillation vials with the glass fiber filter discs and tissue collected into the final vials. Released radioactivity was determined by liquid scintillation spectroscopy.

All data were statistically analyzed as ratios (S2/S1) before conversion to percentage of control values for presentation. The ratio of S2/S1 in the absence of any test drug was 0.54 ± 0.07 (n = 10). An enhancement by test drug would result in a higher ratio and an inhibition in a lower ratio. In this way, differences in response between tissue samples are taken into account and therefore, do not affect the comparison of treatments. In the results, data are expressed as radioactivity released above baseline during the collection interval as a fraction of the total radioactivity in the tissue at the beginning of the collection interval (fractional release, percentage) or as a percentage of the radioactivity released by the control stimulus (percentage of control-stimulated release). Data are presented as a percentage of control-stimulated release for facilitation of comparison across experiments. Under the experimental conditions used, the released radioactivity has been shown to be primarily dopamine (Werling et al., 1988). All statistical analyses were performed by one-way factorial analysis of variance with post hoc Dunnett's. Statistical significance is considered at p < 0.05.

	Results

Top Abstract Materials and Methods Results Discussion References

 
To examine the possibility that steroids could act similarly to identified agonists or antagonists at receptors, we tested several steroids for their ability to regulate NMDA-stimulated [³H]dopamine release via receptors from rat striatal tissue. We first tested single concentrations of progesterone, pregnenolone, DHEA, and testosterone to determine whether they had any effect on NMDA-stimulated [³H]dopamine release. As seen in Fig. 1, neither DHEA at 10 µM (K_i at receptors = 3.7 µM, undifferentiated for subtype; Klein and Musacchio, 1994) nor testosterone at 3 or 10 µM (K_i = 1 µM, undifferentiated for subtype; Su et al., 1988) showed any significant difference from control-stimulated release.

View larger version (40K): [in this window] [in a new window]   Fig. 1. Lack of effect of 10 µM DHEA, 3 or 10 µM testosterone on NMDA-stimulated [3H]dopamine release. Release of [3H]dopamine from slices of rat striatal tissue was stimulated by 25 µM NMDA or 25 µM NMDA in the presence of DHEA or testosterone as indicated. Statistical analysis by analysis of variance, performed on untransformed data (ratios of S2/S1) indicated no significant difference in 25 µM NMDA alone compared with 25 µM NMDA in the presence of DHEA or testosterone. Data are expressed as percentage of control NMDA-stimulated release. n = 3 independent experiments in which each treatment was tested in triplicate. Note break in y-axis.

In preliminary experiments, progesterone at 3 µM and pregnenolone at 1 µM showed an inhibition of NMDA-stimulated [³H]dopamine release. We then constructed concentration-response curves for both these steroids. As seen in Fig. 2A, progesterone inhibited NMDA-stimulated [³H]dopamine release in a concentration-dependent matter. Progesterone has a K_i value of 270 nM at receptors, undifferentiated for subtype (Su et al., 1988). The IC₅₀ for inhibition of release was similar to this value, lying between 100 and 300 nM. Progesterone significantly inhibited release at 300 nM and 1 µM. At 1 µM, the highest concentration tested, progesterone inhibited release approximately 30%, similar to the maximum inhibition produced by (+)-pentazocine that was attributable to receptors (Gonzalez-Alvear and Werling, 1994). To confirm whether the inhibition by progesterone was mediated through receptors, we tested the ₁ receptor-selective antagonist DuP734 (100 nM) and the ₂ receptor-selective antagonist Lu28-179 (1 nM) against 1 µM progesterone (Fig. 2A). Both DuP734 and Lu2-1798 completely reversed the inhibition of release by progesterone to values slightly above control-stimulated release. The elevation above control is not significant for Lu28-179, and although the value for DuP734 achieves statistical significance as differing for NMDA alone, is associated with a high error value.

View larger version (34K): [in this window] [in a new window]   Fig. 2. Concentration-response curves for progesterone (A) and pregnenolone (B) on NMDA-stimulated [3H]dopamine release, and reversal by receptor antagonists. Release of [3H]dopamine from slices of rat striatal tissue was stimulated by 25 µM NMDA alone or 25 µM NMDA in the presence of progesterone or pregnenolone as indicated, with or without the 1 antagonist DuP734 (100 nM) or the 2 antagonist Lu28-179 (1 nM). Data are expressed as percentage of control NMDA-stimulated release. *, significantly different from NMDA alone at p < 0.05. #, significantly different from NMDA in the presence of progesterone or pregnenolone as indicated, p < 0.05. n 3 independent experiments in which each treatment was tested in triplicate. Note breaks in y-axes.

Next, we constructed a concentration-response curve for pregnenolone. As seen in Fig. 2B, the IC₅₀ value for inhibition of release was between 300 nM and 1 µM. Pregnenolone at 3 µM inhibited release approximately 25%. As with progesterone, we also tested pregnenolone (3 µM) with both the ₁ antagonist DuP734 (100 nM) and the ₂ antagonist Lu28-179 (1 nM). Both DuP734 and Lu28-179 completely reversed the inhibition by pregnenolone (Fig. 2B) to levels not different from control-stimulated release.

Because DHEA and testosterone have affinity for receptors, but did not show any inhibition of NMDA-stimulated [³H]dopamine release, we tested whether they might behave as antagonists in our assay. We tested DHEA and testosterone in combination with both progesterone and pregnenolone to examine whether they reversed the inhibition of NMDA-stimulated [³H]dopamine release seen by both progesterone and pregnenolone. Neither DHEA (10 µM) nor testosterone (3 µM) had any effect on the inhibition of [³H]dopamine release seen by either progesterone (Fig. 3A) or pregnenolone (Fig. 3B).

View larger version (29K): [in this window] [in a new window]   Fig. 3. Lack of effect of testosterone or DHEA on the inhibition of NMDA-stimulated [3H]dopamine release by 1 µM progesterone (A) and 3 µM pregnenolone (B). Release of [3H]dopamine from slices of rat striatal tissue was stimulated by 25 µM NMDA alone or 25 µM NMDA in the presence of agonist steroid, as indicated, with or without potential antagonist steroid testosterone (3 µM) or DHEA (10 µM). Data are expressed as percentage of control NMDA-stimulated release. *, significantly different from NMDA alone at p < 0.05. Neither the inclusion of testosterone nor DHEA significantly changed the inhibition produced by progesterone or pregnenolone alone. n = 3 independent experiments in which each treatment was tested in triplicate. Note breaks in y-axes.

To determine whether PKC is involved in the inhibition of NMDA-stimulated [³H]dopamine release, we constructed dose-response curves for the PKC-selective inhibitor LY379196 against both progesterone and pregnenolone. We have previously shown that LY379196 blocked (+)-pentazocine-mediated inhibition of NMDA-stimulated [³H]dopamine release in a concentration-dependent manner (Nuwayhid and Werling, 2003). LY379196 has K_i values at I and II isozymes of 18 and 16 nM, and all other isozymes, including PKC, PKC, PKC, PKC, and PKC >300 nM (Louis Vignati, personal communication). As seen in Fig. 4A, LY379196 completely reversed the inhibition of release by 1 µM progesterone at both 30 and 100 nM. At 30 nM, LY379196 completely reversed the inhibition of release by 3 µM pregnenolone (Fig. 4B).

View larger version (32K): [in this window] [in a new window]   Fig. 4. Reversal of steroid-mediated inhibition of NMDA-stimulated [3H]dopamine release by the PKC-selective inhibitor LY379196. Release of [3H]dopamine from rat striatal slices was stimulated by 25 µM NMDA alone or 25 µM NMDA in the presence of 1 µM progesterone (A) or 3 µM pregnenolone (B), as indicated, with or without the indicated concentration of LY379196. Data are expressed as percentage of control NMDA-stimulated release. *, significantly different from NMDA alone at p < 0.05, n = 3 independent experiments. #, significantly different from 1 µM progesterone or 3 µM pregnenolone without PKC inhibitor at p < 0.05, n = 3 independent experiments in which each treatment was tested in triplicate. Note breaks in y-axes.

Progesterone and pregnenolone are synthesized from cholesterol, as demonstrated in neural cells in culture (Guarneri et al., 2000). We therefore tested cholesterol to determine whether it, as the parent compound, displayed any effects on NMDA-stimulated [³H]dopamine release. Cholesterol (25 µM) did not affect NMDA-stimulated release of [³H]dopamine (Fig. 5).

View larger version (35K): [in this window] [in a new window]   Fig. 5. Lack of effect of cholesterol on NMDA-stimulated [3H]dopamine release. Release of [3H]dopamine from slices of rat striatal tissue was stimulated by 25 µM NMDA alone or 25 µM NMDA in the presence 25 µM cholesterol, as indicated. There was no significant difference in release of [3H]dopamine stimulated by 25 µM NMDA alone compared with 25 µM NMDA in the presence of 25 µM cholesterol. Data are expressed as percentage of control NMDA-stimulated release. n = 3 independent experiments in which each treatment was tested in triplicate. Note break in y-axis.

Last, to verify the effects seen by pregnenolone on NMDA-stimulated [³H]dopamine release were attributed to pregnenolone and not dependent upon its conversion to progesterone or other metabolite, we tested pregnenolone in the presence of 20 µM trilostane. Trilostane is an inhibitor of 3-hydroxysteriod dehydrogenase, an enzyme that converts pregnenolone to progesterone (K_i = 50 nM; Takahashi et al., 1990). As seen in Fig. 6, inhibition of [³H]dopamine release by 3 µM pregnenolone in the presence of trilostane was not significantly different compared with the inhibition of [³H]dopamine release by 3 µM pregnenolone alone. We also verified that progesterone was acting through receptors and not progesterone receptors by testing 1 µM progesterone in the presence of 10 µM mifepristone, a progesterone receptor antagonist. As seen in Fig. 7, there was no difference in the inhibition seen by 1 µM progesterone alone compared with 1 µM progesterone in the presence of 10 µM mifepristone.

View larger version (31K): [in this window] [in a new window]   Fig. 6. Lack of significant effect of trilostane on pregnenolone-mediated inhibition of NMDA-stimulated [3H]dopamine. Release of [3H]dopamine from slices of rat striatal tissue was stimulated by 25 µM NMDA alone or 25 µM NMDA in the presence 3 µM pregnenolone, as indicated, with or without 25 µM trilostane. Data are expressed as percentage of control NMDA-stimulated release. *, significantly different from NMDA alone at p < 0.05, n = 3 independent experiments in which each treatment was tested in triplicate. Note break in y-axis.

View larger version (33K): [in this window] [in a new window]   Fig. 7. Lack of effect of mifepristone on the inhibition of NMDA-stimulated [3H]dopamine release by 1 µM progesterone. Release of [3H]dopamine from slices of rat striatal tissue was stimulated by 25 µM NMDA alone or 25 µM NMDA in the presence 1 µM pregnenolone, as indicated, with or without mifepristone. Data are expressed as percentage of control NMDA-stimulated release. *, significantly different from NMDA alone at p < 0.05, n = 3 independent experiments in which each treatment was tested in triplicate. Note break in y-axis.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
The identity of the endogenous ligand for receptors has been equivocal. Su et al. (1988) found that progesterone, deoxycortisone, and testosterone competed for [³H]SKF10,047 at ₁ sites in guinea pig brain tissue and proposed steroids as the endogenous ligands. Several studies have now demonstrated that steroids are synthesized in the brain (Hu et al., 1987; Jung-Testas et al., 1989; Guarneri et al., 2000).

Steroids exhibit genomic and nongenomic effects (Ruppert and Holsboer, 1999). In the current study, we examined presumably nongenomic effects of steroids on NMDA-stimulated [³H]dopamine release in rat striatal tissue via receptors. The effects on regulation of dopamine release occur within a relatively short time frame because the length of exposure of tissue to steroid is 12 min, not likely sufficient to produce changes in protein expression. If steroids are endogenous ligands for receptors they should behave similarly to prototypic ligands, such as (+)-pentazocine.

We found that both progesterone and pregnenolone inhibited NMDA-stimulated [³H]dopamine release. Both inhibited release in a concentration-dependent manner, with a maximum of about 25 to 30%, similar to the inhibition seen by (+)-pentazocine in studies by Gonzalez-Alvear and Werling (1994, 1995). The IC₅₀ value of progesterone (300 nM) for inhibition of NMDA-stimulated [³H]dopamine release was similar to its K_i value of 270 nM in competing for binding to receptors (Su et al., 1988). Pregnenolone showed an IC₅₀ value in the range of 300 nM to 1 µM. A K_i value at receptors in brain tissue has not been reported, but we found that pregnenolone competed for ₁ binding with a K_i value of 980 ± 340 nM in SH-SY5Y cells (Werling, 2002). Su et al. (1988) reported a K_i value of 3.2 µM for pregnenolone sulfate binding to ₁ receptors. These findings support that pregnenolone acts via receptors to inhibit NMDA-stimulated [³H]dopamine release.

The hypothesis that progesterone and pregnenolone act as agonists in our assay was confirmed by the action of antagonists. The inhibition of NMDA-stimulated [³H]dopamine release by 1 µM progesterone and 3 µM pregnenolone was fully reversed by the ₁ antagonist DuP734 (K_i = 10 nM) (Culp et al., 1992) at 100 nM and the ₂ antagonist Lu28-179 (K_i = 0.12 nM) (Moltzen et al., 1995) at 1 nM. The reversal seen by 100 nM DuP734 was somewhat above control, although associated with a relatively high error determination. It is possible that there is antagonism of tone exerted by endogenous steroids. However, the antagonists had no effect on basal release, which argues against this possibility. The action seen by both DuP734 and Lu28-179 suggest that the inhibition of [³H]dopamine release is mediated through both ₁ and ₂ receptor subtypes. This is a contrast to our findings (Gonzalez-Alvear and Werling, 1994, 1995) in which components of (+)-pentazocine-mediated inhibition were clearly attributable to either ₁ or ₂ receptors based on reversal by subtype-selective antagonists. However, in our assays examining the effects of ₂ agonists on amphetamine-stimulated [³H]dopamine release from rat striatal slices, we found similar antagonism of effect by ₁ and ₂ antagonists (Liu et al., 2001) to that seen for the current steroid experiments. The ₁ and ₂ receptors are relatively small (₁ = 28 kDa, Hanner et al., 1996; ₂ = 22 kDa, Hellewell and Bowen, 1990). Perhaps upon activation of receptor subtypes by progesterone and pregnenolone the receptors interact with each other, which in turn inhibits [³H]dopamine release. In this situation, competing off the steroid agonist with either ₁ or ₂ antagonists would prevent regulation of dopamine release. Reports in which receptor protein was purified and detected via photoaffinity labeling (Schuster et al., 1995) or with antibody selective for receptor (Hanner et al., 1996), show a band with a molecular weight of approximately 60 kDa, which could be a dimer of ₁ and/or ₂ receptors. Neuroactive steroids are known to modulate the actions of GABA_A and NMDA receptors (Ruppert and Holsboer, 1999). Although it cannot be absolutely excluded that the effects of the steroids observed in the current study involve actions via one of these receptors, the regulation of dopamine release by the steroids is presumably via actions at the dopaminergic nerve terminal, because receptors regulating dopamine release have been localized to that location (Gonzalez-Alvear and Werling, 1995). Regardless of whether GABA_A or NMDA receptors contribute in some way to the overall response, the effects of progesterone and pregnenolone are both completely reversed in the current study by receptor antagonists.

The concentrations of DHEA and testosterone tested were chosen based on their reported K_i values from binding studies. Although both competed for receptor binding (Su et al., 1988; Klein and Musacchio, 1994), our data do not indicate that the receptor subtype(s) involved in the regulation of dopamine release are sensitive to these steroids. Neither showed an inhibition of stimulated dopamine release, and when tested for potential antagonist activity, neither reversed the inhibition of [³H]dopamine release by progesterone or pregnenolone. DHEA and testosterone may bind to receptors but not have either agonist or antagonist properties in our system. It is possible that higher or lower concentrations could have produced effects, although this would not be predicted based on reported affinities at receptors. Further confirming that agonist properties are conferred only upon specific steroids, and not the heterocyclic steroidal structure in general, was the finding that cholesterol, the parent compound from which steroids are derived, had no effect on NMDA-stimulated [³H]dopamine release.

We confirmed that the effects displayed by pregnenolone were due to pregnenolone itself and not its metabolite progesterone, using trilostane, an inhibitor of 3-hydroxysteroid dehydrogenase enzyme that converts pregnenolone into progesterone. Therefore, both progesterone and pregnenolone seem to act as receptors agonists in the regulation of dopamine release.

Monnet et al. (1995) showed that DHEA S potentiated [³H]norepinephrine release from rat hippocampal slices and this response was reversed by both antagonists haloperidol and BD1063. In a later article (Monnet et al., 1996), they also showed regulation of norepinephrine release by other steroids, but with a different pharmacology than ours. Our data show regulation of NMDA-stimulated [³H]dopamine release by steroids is inhibitory. This could be due to the difference in the neurotransmitter studied or other experimental variables. We have previously shown that receptors that regulate dopamine release from striatum are located on dopaminergic nerve terminals, but those regulating norepinephrine release are not. Therefore, the strength of the stimulus and the circuitry involved in hippocampus is likely to be much more complex. Monnet et al. (1995) used a concentration of NMDA 4 times that used by us in the current experiment and in our previous experiments on norepinephrine. The higher NMDA concentration could activate multiple other neurons upon which sigma receptors are located. Monnet et al. (1995) identified that the effects observed for some agonists were mediated by different populations of receptor subtypes depending upon the agonist used. It seems that our responses are due to activation of only ₁ and ₂ subtypes only as identified by selective antagonists.

Other groups have also reported effects of steroids that were mediated by receptors. PREG S increase spontaneous glutamate release via activation of a presynaptic G_i/o-coupled receptor (Meyer et al., 2002). Because steroid sulfotransferases and sulfatases are present in the central nervous system (Rajkowski et al., 1997), both sulfated and nonsulfated forms could be present in the brain and modulate neurotransmitter release. However, the permeability of steroids is reduced by the addition of sulfate; if receptors are intracellular, as suggested by McCann and Su (1994) and Vilner and Bowen (2000), the actions of sulfated steroids would be limited. Unsulfated steroids would have to enter the cell and be subsequently sulfated to become active. It is also possible that sulfated steroids could be concentrated and stored in vesicles (Gibbs and Farb, 2000). However, the weak activities of sulfatases and sulfotransferases make the conversion of steroids in vivo doubtful (Baulieu and Robel, 1996).

Studies have now implicated the PKC signaling system in receptor mediated processes. GF109203x, a PKC inhibitor, abolished ₂ receptor-mediated regulation of dopamine transporter activity (Derbez et al., 2002). Morin-Surin et al. (1999) showed a parallel translocation of receptors and PKCI and PKCII from the cytosol to the plasma membrane upon agonist application. They also showed a time-dependent desensitization in the ability of (+)-pentazocine to reduce the firing rate in rat hypoglossal neurons. This desensitization may have been attributed to the desensitization of PKC itself. In our studies, LY379196, a PKC-selective inhibitor, blocked the inhibition of [³H]dopamine release produced by (+)-pentazocine (Nuwayhid and Werling, 2003). U73122 [GenBank] , a PLC inhibitor, also blocked (+)-pentazocine-mediated regulation. This suggests that in order for (+)-pentazocine to exert its inhibition of dopamine release the PLC/PKC system must be intact. PKC activation has also been linked to inhibition of NMDA-stimulated Ca²⁺ changes in cerebellar granular cells (Snell et al., 1994).

In the current study, we determined that the inhibition of NMDA-stimulated [³H]dopamine release by steroids is dependent upon PKC activation. Steroids are known to interact with the PKC pathway. Progesterone can rapidly stimulate phosphatidylinositol bisphosphate hydrolysis, leading to the formation of diacylglycerol and inositol triphosphate, presumably due to the action of Ca²⁺-dependent PKC (Thomas and Meizel, 1989). Estrogen increased inositol triphosphate concentrations and stimulated PKC levels in membrane fraction of HEPG2 cells through a nonclassical steroid mechanism (Marino et al., 1998). Last, in studies by Condliffe et al. (2001), 17--estradiol regulated Cl^- secretion in rat colonic epithelium, and regulation is blocked by the chelation of Ca²⁺ with BAPTA or the PKC inhibitor chelerythrine. In our study, steroids exhibited the same effects of (+)-pentazocine in the presence of LY379196, an inhibitor of PKC isozymes. This reinforces the possibility that steroids have nongenomic actions and can signal through PLC/PKC via their actions at receptors.

In conclusion, both progesterone and pregnenolone have been identified as receptor agonists in the modulation of NMDA-stimulated [³H]dopamine release. We found them to behave similarly to prototypic ligands, such as (+)-pentazocine. In addition, we have shown that the inhibition of NMDA-stimulated [³H]dopamine release mediated by progesterone and pregnenolone involves a PKC signaling system most likely to involve the PKC isozyme. Our findings in this study further support steroids as candidates for endogenous ligands at receptors.

	Acknowledgements

 
We thank Dr. John Puddefoot (Queen Mary and Westfield College) for the gift of trilostane, Dr. Rob Zaczek (DuPont Merck) for the gift of DuP734, and Dr. Connie Sanchez (H. Lundbeck) for the gift of Lu28-179. We also thank Dr. Nancy Pilotte (National Institute on Drug Abuse) for helpful suggestions regarding experimental design using steroids.

	Footnotes

 
This work was supported by a grant from National Institute on Drug Abuse (DA06667) and a Faculty Enhancement Research Award from George Washington University Medical Center (to L.L.W.).

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

DOI: 10.1124/jpet.103.052324.

ABBREVIATIONS: NMDA, N-methyl-D-aspartate; DHEA S, dehydroepiandrosterone sulfate; PREG S, pregnenolone sulfate; DHEA, dehydroepiandrosterone; PKC, protein kinase C; PLC, phospholipase C; MKB, modified Krebs-HEPES buffer; S1, first stimulus; ISI, inter stimulus interval; S2, second stimulus; LY379196, 5,21:12,17-dimetheno-18H-dibenzo[i,o]pyrrolo[3,4-1][1,8]diacyclohexadecine-18,20(19H)-dione,8-[(dimethylamino)methyl]-6,7,8,9,10,11-hexahydro-monomethanesulfonate (9Cl); BD1063, 1[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine; DuP734, 1-(cyclopropylmethyl)-4-2'-4''flurophenyl)-2'oxoethyl)piperidine HBr; Lu28-179, 1'-[4-[1-(4-fluorophenyl)-1-H-indol-3-yl]-1-butyl]spiro[iso-benzofuran-1(3H),4'piperidine]; GF109203x, 3[1-[3-(dimethylamino)propyl]-1H-indol-3-yl)-1-H-pyrprole-2,5-dione; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; SKF10,047, n-allylnormetazocine; BD737, 1S,2R-(-)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)-cyclyohexylamine; U73122 [GenBank] , 1(6-((17-b-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione.

Address correspondence to: Dr. Linda L. Werling, Department of Pharmacology, The George Washington University, 2300 Eye St., NW, Washington, DC 20037. E-mail: phmllw{at}gwumc.edu

	References

Top Abstract Materials and Methods Results Discussion References

 

Bastianetto S, Monnet F, Junien J-L, and Quirion R (1999) Steroidal modulation of sigma receptor function, in Contemporary Endocrinology: Neurosteroids: A New Regulatory Function on the Nervous System (Baulieu EE, Robel P, and Schumacher M eds) pp 191-205, Humana Press, Totowa, NJ.

Baulieu EE and Robel P (1996) Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive steroids. J Endocrinol 150 (Suppl): S221-S239.[Medline]

Bergeron R, de Montigny C, and Debonnel G (1996) Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 16: 1193-1202.[Abstract/Free Full Text]

Condliffe SB, Doolan CM, and Harvey BJ (2001) 17--Estradiol acutely regulates Cl^- secretion in rat distal colonic epithelium. J Physiol (Lond) 530: 47-54.[Abstract/Free Full Text]

Culp SG, Rominger D, Tam SW, and De Souza EB (1992) [³H]DuP 734 [1-(cyclopropylmethyl)-4-(2'-(4''-fluorophenyl)-2'-oxoethyl)-piperidine HBr]: a receptor binding profile of a high-affinity novel sigma receptor ligand in guinea pig brain. J Pharmacol Exp Ther 263: 1175-1187.[Abstract/Free Full Text]

Derbez AE, Moody RM, and Werling LL (2002) Sigma₂ receptor regulation of dopamine transporter activity via protein kinase C. J Pharmacol Exp Ther 301: 306-314.[Abstract/Free Full Text]

Falkenstein E, Tillmann H-C, Christ M, Feuring M, and Wehling M (2000) Multiple actions of steroid hormones—a focus on rapid, nongenomic effects. Pharm Rev 52: 513-555.[Abstract/Free Full Text]

Gibbs T and Farb D (2000) Dueling engimas: neurosteroids and sigma receptors in the limelight. Sci STKE Nov 28 2000(60): PE1.

Gonzalez-Alvear GM and Werling LL (1994) Regulation of [³H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther 271: 212-219.[Abstract/Free Full Text]

Gonzalez-Alvear GM and Werling LL (1995) Sigma₁ receptors in rat striatum regulate NMDA stimulated [³H]dopamine release via a presynaptic mechanism. Eur J Pharmacol 294: 713-719.[CrossRef][Medline]

Guarneri P, Cascio C, Piccoli T, Piccoli F, and Guarneri R (2000) Human neuroblastoma SH-SY5Y cell line: neurosteroid-producing cell line relying on cytoskeletal organization. J Neurosci Res 60: 656-665.[CrossRef][Medline]

Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kemper E, and Glossman H (1996) Purification, molecular cloning and expression of the mammalian sigma₁ binding site. Proc Natl Acad Sci USA 93: 8072-8077.[Abstract/Free Full Text]

Hellewell SB and Bowen WD (1990) A sigma-like binding site in rat pheochromocytoma (PC12): decreased affinity for (+)benzomorphans and lower molecular weight suggest a different receptor from that of guinea pig brain. Brain Res 527: 244-253.[CrossRef][Medline]

Hu ZY, Bourreau E, Jung-Testas I, Robel P, and Baulieu EE (1987) Neurosteroids: oligodendrocyte mitochondria convert cholesterol to pregnenolone. Proc Natl Acad Sci USA 84: 8215-8219.[Abstract/Free Full Text]

Izenwasser S, Thompson-Montgomery DT, Deben SE, Chowdhury IN, and Werling LL (1998) Modulation of amphetamine-stimulated (transporter-mediated) dopamine release by sigma₂ receptor agonists and antagonists in vitro. Eur J Pharmacol 346: 189-196.[CrossRef][Medline]

Jung-Testas Z, Hu ZY, Baulieu EE, and Robel P (1989) Neurosteroids: biosynthesis of pregnenolone and progesterone in primary cultures of rat glial cells. Endocrinology 125: 2083-2091.[Abstract]

Klein M and Musacchio JM (1994) Effects of cytochrome P-450 ligands on the binding of [³H]dextromethorphan and sigma ligands on to guinea pig brain, in Sigma Receptors (Itzhak Y ed) pp 243-262, Academic Press, San Diego.

Liu X, Nuwayhid S, Christie M, Kassiou M, and Werling LL (2001) Trishmocubanes: novel ligands modulate amphetamine-stimulated [³H]dopamine release. Eur J Pharmacol 422: 39-45.[CrossRef][Medline]

Marino PJ, Pallottini V, and Trentalance A (1998) Estrogens cause rapid activation of IP3-PKC signal transduction in HEPG2 cells. Biochem Biophys Res Commun 245: 254-258.[CrossRef][Medline]

Martin WR, Eades CG, Thompson JA, Huppler RE, and Gilbert PE (1976) The effects of morphine- and nalorphine-type drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517-532.[Abstract/Free Full Text]

Maurice T, Phan VL, Urani A, and Guillemain (2001) Differential involvement of the sigma-1 receptor in the anti-amnesic effect of neuroactive steroids as demonstrated using an antisense oligonucleotide strategy in the mouse. Br J Pharmacol 134: 1731-1741.[CrossRef][Medline]

Maurice T, Phan VL, Urani A, Kamei H, Noda Y, and Nabeshima T (1999) Neuroactive steroids as endogenous effectors for the sigma1 (1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 81: 125-155.[CrossRef][Medline]

McCann DM and Su TP (1994) Sigma₁ and sigma₂ sites in rat brain: comparison of regional, ontogenetic and subcellular patterns. Synapse 17: 182-189.[CrossRef][Medline]

Meyer DA, Carta M, Partridge D, Covey DF, and Valenzuela CF (2002) Neurosteroids enhance spontaneous glutamate release in hippocampal neurons: possible role of metabotropic ₁ like receptors. J Biol Chem 277: 28725-28732.[Abstract/Free Full Text]

Moltzen EK, Perregard TA, and Meier E (1995) ligands with subnanomolar affinity and preference for the ₂ binding site. 2. Spiro-joined benzofuran, isobenzofuran and benzopyran piperidines. J Med Chem 38: 2009-2017.[CrossRef][Medline]

Monnet FP, Mahe V, Robel P, and Baulieu EE (1995) Neurosteroids, via sigma receptors, modulate the [³H]norepinephrine release evoked by NMDA in the rat hippocampus. Proc Natl Acad Sci USA 92: 3774-3778.[Abstract/Free Full Text]

Morin-Surin MP, Collin T, Denavit-Saubie M, Baulieu EE, and Monnet FP (1999) Intracellular sigma₁ receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc Natl Acad Sci USA 96: 8196-8199.[Abstract/Free Full Text]

Nuwayhid S and Werling LL (2003) Sigma₁ receptor agonist-mediated regulation of NMDA-stimulated [³H]dopamine release in dependent upon protein kinase C. J Pharmacol Exp Ther 304: 364-369.[Abstract/Free Full Text]

Rajkowski KM, Robel P, and Baulieu EE (1997) Hydroxysteroid sulfotransferase activity in the rat brain and liver as a function of age and sex. Steroids 62: 427-436.[CrossRef][Medline]

Ruppert R and Holsboer F (1999) Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22: 410-416.[CrossRef][Medline]

Schuster DI, Arnold FJ, and Murphy RB (1995) Purification, pharmacological characterization and photoaffinity labeling of sigma receptors from rat and bovine brain. Brain Res 670: 14-28.[CrossRef][Medline]

Snell LD, Iorio KR, Tbakoff B, and Hoffman PL (1994) Protein kinase C activation attenuates NMDA-induced increases in intracellular calcium in cerebellar granule cells. J Neurochem 62: 1783-1789.[Medline]

Su TP, London ED, and Jaffe JH (1988) Steroid binding at sigma receptors suggest a link between endocrine, nervous and immune systems. Science (Wash DC) 240: 219-221.[Abstract/Free Full Text]

Swartz S, Pohl P, and Zhou GZ (1989) Steroid binding at -"opioid" receptors. Science (Wash DC) 246: 1635-1637.[Free Full Text]

Takahashi M, Luu-The V, and Labrie F (1990) Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3-hydroxysteroid dehydrogenase/5-4-ene isomerase activity. J Steroid Biochem Mol Biol 37: 231-236.[CrossRef][Medline]

Thomas P and Meizel S (1989) Phosphatidylinositol 4,5 biphosphate hydrolysis in human sperm stimulated with follicular fluid or progesterone is dependent on upon Ca²⁺ influx. J Biochem 264: 539-546.

Vilner BJ and Bowen WD (2000) Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 292: 900-911.[Abstract/Free Full Text]

Werling LL (2002) Sigma receptor-active steroids and neurotransmitter release. Int J Psychopharmacol 5: S28.

Werling LL, Frattali A, Portoghese PS, Takemori AE, and Cox BM (1988) Kappa receptor regulation of dopamine release from striatum and cortex of rat and guinea pig. J Pharmacol Exp Ther 246: 282-286.[Abstract/Free Full Text]

This article has been cited by other articles:

				T. Hayashi and T.-P. Su Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation PNAS, October 12, 2004; 101(41): 14949 - 14954. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.103.052324v1 306/3/934    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuwayhid, S. J. Articles by Werling, L. L. Search for Related Content PubMed PubMed Citation Articles by Nuwayhid, S. J. Articles by Werling, L. L.